Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(7):978-992.
doi: 10.2174/1570159X15666170915142727.

Novel Therapeutics in Glaucoma Management

Claudio Bucolo  1   2 , Chiara Bianca Maria Platania  1 , Filippo Drago  1   2 , Vincenza Bonfiglio  3 , Michele Reibaldi  2   3 , Teresio Avitabile  2   3 , Maurizio Uva  2   3
Affiliations
Review

Novel Therapeutics in Glaucoma Management

Claudio Bucolo et al. Curr Neuropharmacol. 2018.

Abstract

Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.

Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.

Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.

Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.

Keywords: Glaucoma; Rho kinase inhibitors; anti-glaucoma drugs; dopamine ligands; histone deacetylase inhibitors; intraocular pressure; nitric oxide; purinergic ligands; retinal ganglion cells..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
PubMed entries on neuroprotection strategy and glaucoma treatment. Entries have been retrieved from PubMed using the following formula in the advanced search PubMed engine: “search terms”; YYYY:YYYY [edat]; (e.g. “glaucoma AND IOP”; 2007:2012 [edat]).
See this image and copyright information in PMC

References

    1. Bucolo C., Platania C.B., Reibaldi M., Bonfiglio V., Longo A., Salomone S., Drago F. Controversies in glaucoma: current medical treatment and drug development. Curr. Pharm. Des. 2015;21(32):4673–4681. [http://dx.doi.org/10.2174/1381612821666150909095553]. - PubMed
    1. Hoban K., Peden R., Megaw R., Halpin P., Tatham A.J. 24-hour contact lens sensor monitoring of intraocular pressure-related profiles in normal-tension glaucoma and rates of disease progression. Ophthalmic Res. 2017;57(4):208–215. [http://dx.doi.org/10.1159/ 000455153]. - PubMed
    1. Collaborative normal-tension glaucoma study group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 1998;126(4):498–505. [http://dx.doi.org/10.1016/S0002-9394(98)00272-4]. - PubMed
    1. Morgan W.H., Balaratnasingam C., Lind C.R., Colley S., Kang M.H., House P.H., Yu D.Y. Cerebrospinal fluid pressure and the eye. Br. J. Ophthalmol. 2016;100(1):71–77. [http://dx.doi.org/10. 1136/bjophthalmol-2015-306705]. - PubMed
    1. Stowell C., Burgoyne C.F., Tamm E.R., Ethier C.R. Biomechanical aspects of axonal damage in glaucoma: A brief review. Exp. Eye Res. 2017;157:13–19. [http://dx.doi.org/10.1016/j.exer. 2017.02.005]. - PMC - PubMed

Substances

LinkOut - more resources